nabilone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
cannabinoid receptors agonists	1862	51022-71-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nabilone cesamet LY 109514 LY-109514	cannabinol deriv; RN given refers to cpd without isomeric designation; structure Molecular weight: 372.55 Formula: C24H36O3 CLOGP: 6.72 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -5.88 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nabilone
cesamet
LY 109514
LY-109514

cannabinol deriv; RN given refers to cpd without isomeric designation; structure

Molecular weight: 372.55
Formula: C24H36O3
CLOGP: 6.72
LIPINSKI: 1
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -5.88
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Dec. 26, 1985	FDA	MEDA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
White blood cell count abnormal	360.33	25.48	85	4568	6157	63478212
Musculoskeletal stiffness	152.27	25.48	118	4535	184500	63299869
Gait disturbance	144.38	25.48	114	4539	183064	63301305
Somatic symptom disorder	131.53	25.48	32	4621	2628	63481741
Sacroiliitis	130.01	25.48	33	4620	3224	63481145
Rheumatoid arthritis	117.81	25.48	117	4536	253702	63230667
Insomnia	104.97	25.48	102	4551	215150	63269219
Drug hypersensitivity	93.30	25.48	114	4539	310573	63173796
Therapeutic product effect incomplete	90.18	25.48	74	4579	124982	63359387
Mood altered	81.02	25.48	33	4620	14710	63469659
Therapeutic response shortened	80.70	25.48	31	4622	11857	63472512
Acute psychosis	78.60	25.48	21	4632	2504	63481865
Mean cell haemoglobin concentration abnormal	73.50	25.48	12	4641	120	63484249
Pain	67.37	25.48	159	4494	740469	62743900
Lip and/or oral cavity cancer	61.13	25.48	14	4639	884	63483485
Cognitive disorder	60.06	25.48	42	4611	55773	63428596
Occult blood	55.97	25.48	14	4639	1287	63483082
Dystonia	49.89	25.48	23	4630	13796	63470573
Psychotic disorder	49.52	25.48	28	4625	25684	63458685
Anaphylactic reaction	47.31	25.48	39	4614	66061	63418308
Cannabinoid hyperemesis syndrome	44.17	25.48	7	4646	57	63484312
Thyroid cancer	43.02	25.48	16	4637	5595	63478774
Dyskinesia	34.21	25.48	24	4629	31978	63452391
Iron deficiency	32.39	25.48	14	4639	7216	63477153
Fibromyalgia	29.82	25.48	33	4620	80387	63403982
Ankylosing spondylitis	27.44	25.48	14	4639	10460	63473909
Orthostatic hypotension	27.25	25.48	22	4631	36138	63448231
C-reactive protein increased	27.04	25.48	34	4619	94673	63389696

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pelvic pain	98.54	42.11	23	1641	2457	34952810
Terminal insomnia	79.36	42.11	15	1649	573	34954694
Injection site warmth	60.60	42.11	15	1649	2047	34953220
Neck pain	49.13	42.11	24	1640	25325	34929942
Ocular hyperaemia	49.12	42.11	19	1645	11433	34943834
Kidney infection	46.34	42.11	15	1649	5379	34949888
Oral herpes	45.93	42.11	15	1649	5532	34949735
Immune-mediated hepatitis	44.96	42.11	12	1652	2203	34953064
Pain	43.68	42.11	51	1613	204624	34750643
Injection site mass	43.31	42.11	15	1649	6611	34948656

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Somatic symptom disorder	135.17	21.94	32	5431	2505	79736420
Sacroiliitis	127.55	21.94	33	5430	3721	79735204
Therapeutic product effect incomplete	84.38	21.94	73	5390	141572	79597353
Therapeutic response shortened	77.42	21.94	32	5431	15831	79723094
Mood altered	77.07	21.94	33	5430	17814	79721111
Acute psychosis	69.52	21.94	21	5442	4159	79734766
Ankylosing spondylitis	60.84	21.94	25	5438	12180	79726745
Lip and/or oral cavity cancer	59.07	21.94	14	5449	1099	79737826
Terminal insomnia	57.83	21.94	14	5449	1203	79737722
Mean cell haemoglobin concentration abnormal	57.46	21.94	10	5453	162	79738763
Cognitive disorder	56.29	21.94	43	5420	69883	79669042
Occult blood	53.00	21.94	14	5449	1709	79737216
Pelvic pain	48.87	21.94	22	5441	13359	79725566
Thyroid cancer	44.13	21.94	16	5447	5572	79733353
Cannabinoid hyperemesis syndrome	44.11	21.94	7	5456	62	79738863
Dystonia	41.83	21.94	23	5440	21376	79717549
Psychotic disorder	39.01	21.94	28	5435	41374	79697551
Fibromyalgia	37.92	21.94	33	5430	64307	79674618
Immune-mediated hepatitis	34.70	21.94	12	5451	3644	79735281
Musculoskeletal pain	33.32	21.94	38	5425	102316	79636609
Blood pressure increased	31.70	21.94	54	5409	211306	79527619
Kidney infection	30.80	21.94	19	5444	21832	79717093
Dyskinesia	28.48	21.94	24	5439	44749	79694176
Pain	28.47	21.94	109	5354	703693	79035232
Iron deficiency	28.10	21.94	14	5449	10640	79728285
Chest injury	25.77	21.94	9	5454	2812	79736113
Neck pain	24.53	21.94	28	5435	75389	79663536
Ocular hyperaemia	24.13	21.94	18	5445	28188	79710737
Injection site warmth	23.78	21.94	14	5449	14793	79724132
Feeling hot	22.58	21.94	24	5439	59710	79679215
Heart rate increased	22.40	21.94	34	5429	120690	79618235
Spinal osteoarthritis	22.05	21.94	14	5449	16913	79722012

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A04AD11	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
FDA CS	M0003267	Cannabinoids
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
FDA EPC	N0000175782	Cannabinoid

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chemotherapy-induced nausea and vomiting	indication	236084000
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Schizophrenia	contraindication	58214004	DOID:5419
Hepatic failure	contraindication	59927004
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Mania	contraindication	231494001
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN	AGONIST	Ki	8.40	CHEMBL	CHEMBL
Cannabinoid receptor 2	GPCR	P34972	CNR2_HUMAN		Ki	8.20	CHEMBL
Cannabinoid receptor 1	GPCR		CNR1_RAT		Ki	8.66	CHEMBL
Cannabinoid receptor 2	GPCR		CNR2_MOUSE		Ki	8.74	CHEMBL

External reference:

ID	Source
4019352	VUID
N0000147524	NUI
D05099	KEGG_DRUG
4019352	VANDF
C0068333	UMLSCUI
CHEBI:135574	CHEBI
CHEMBL2218896	ChEMBL_ID
CHEMBL947	ChEMBL_ID
DB00486	DRUGBANK_ID
C011941	MESH_SUPPLEMENTAL_RECORD_UI
5284592	PUBCHEM_CID
9071	IUPHAR_LIGAND_ID
3930	INN_ID
2N4O9L084N	UNII
31447	RXNORM
15778	MMSL
38357	MMSL
52672	MMSL
d04587	MMSL
001686	NDDF
322124005	SNOMEDCT_US
395806009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cesamet	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1231	CAPSULE	1 mg	ORAL	NDA	22 sections
Cesamet	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1231	CAPSULE	1 mg	ORAL	NDA	22 sections